Prognostic Role of Lipoprotein(a) in Elective Percutaneous Coronary Revascularization

Assessment of Lipoprotein(a) in Patients Undergoing Elective Percutaneous Coronary Revascularization: Implications for Cardiovascular Risk Stratification

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07197242

Enrollment

156

Registered

2025-09-29

Start date

2026-10-01

Completion date

2027-12-30

Last updated

2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PCI

Keywords

PCI, coronary artery disease

Brief summary

The study investigates the role of Lipoprotein(a) \[Lp(a)\] levels in predicting cardiovascular risk and adverse events in patients undergoing elective percutaneous coronary intervention (PCI).

Detailed description

his is a multicenter prospective observational cohort study conducted at Assiut University Heart Hospital and affiliated centers. The study focuses on patients undergoing elective (non-ACS) PCI for stable coronary artery disease. Baseline Lp(a) levels will be measured pre-PCI using isoform-insensitive immunoassays, and patients will be followed for 24 months to document cardiovascular outcomes. The primary goal is to assess whether elevated Lp(a) (≥125 nmol/L) independently predicts 2-year major adverse cardiovascular events (MACE) beyond conventional risk factors and procedural complexity. The study also aims to evaluate the prevalence of elevated Lp(a) among this population and its incremental prognostic value for refining risk stratification models such as SYNTAX II/ACEF. Collected blood samples will be stored in a biobank for future exploratory analyses.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults aged 18 years or older Undergoing elective PCI for stable coronary artery disease Ability to provide informed consent Willingness to undergo blood sampling prior to PCI

Exclusion criteria

* Acute coronary syndrome within 30 days Cardiogenic shock Prior heart transplant or left ventricular assist device (LVAD) Life expectancy less than 1 year due to non-cardiac causes Participation in a blinded Lp(a)-lowering outcome trial at the time of enrollment

Design outcomes

Primary

Measure	Time frame	Description
Incidence of major adverse cardiovascular events (MACE)	one year	Incidence of all non-fatal myocardial infarction, and ischemia-driven target vessel revascularization or or definite/probable stent thrombosis.

Outcome results